The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
A prodrug of green tea polyphenol (–)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer
Abstract
Anti-angiogenesis effect of a prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate (Pro-EGCG) in malignant tumors is not well studied. Here, we investigated how the treatment with Pro-EGCG inhibited tumor angiogenesis in endometrial cancer. Tumor xenografts of human endometrial cancer were established and subjected to microarray analysis after Pro-EGCG treatment. First, we showed Pro-EGCG inhibited tumor angiogenesis in xenograft models through down-regulation of vascular endothelial growth factor A (VEGFA) and hypoxia inducible factor 1 alpha (HIF1α) in tumor cells and chemokine (C-X-C motif) ligand 12 (CXCL12) in host stroma by immunohistochemical staining. Next, we investigated how HIF1α/VEGFA was down-regulated and how the reduction of CXCL12 inhibited tumor angiogenesis. We found that VEGFA secretion from endometrial cancer cells was decreased by Pro-EGCG treatment through inhibiting PI3K/AKT/mTOR/HIF1α pathway. Furthermore, the down-regulation of CXCL12 in stromal cells by Pro-EGCG treatment restricted migration and differentiation of macrophages thereby inhibited infiltration of VEGFA-expressing tumor-associated macrophages (TAMs). Taken together, we demonstrated that treatment with Pro-EGCG not only decreases cancer cell-secreted VEGFA but also inhibits TAM-secreted VEGFA in endometrial cancer. These findings demonstrate that Pro-EGCG is a novel angiogenesis inhibitor for endometrial cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Numerous studies, both in vitro using various cancer cell lines and in vivo in animal models, have consistently demonstrated the ability of EGCG to inhibit the initiation, promotion, and progression of different types of tumors.141–145”
From Drug repurposing for cancer therapy (2024) · cites this paper as [144]
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,891
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Singh, B. N., Shankar, S., & Srivastava, R. K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.093 · Cited by 1,652
PI3K/AKT/mTOR Pathway in Angiogenesis
Karar, J., & Maity, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00051 · Cited by 1,493
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0609385 · Cited by 1,456
Genin, M., Clement, F., Fattaccioli, A., Raes, M., & Michiels, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1546-9 · Cited by 1,090
Flagged first, then by citations
Research works printed but not linked: 1
- Chanmee, 2014, vol. 6, 1670
Cited by
Sorted by citations
Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine
Luo, H., Vong, C. T., Chen, H., Gao, Y., Lyu, P., Qiu, L., Zhao, M., Liu, Q., Cheng, Z., Zou, J., et al. (2019) · Chinese Medicine · doi:10.1186/s13020-019-0270-9 · Cited by 569
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Almatroodi, S. A., Almatroudi, A., Khan, A. A., Alhumaydhi, F. A., Alsahli, M. A., & Rahmani, A. H. (2020) · Molecules · doi:10.3390/molecules25143146 · Cited by 369
Bioavailability of Tea Catechins and Its Improvement
Cai, Z., Li, X.-M., Liang, J.-P., Xiang, L., Wang, K., Shi, Y., Yang, R., Shi, M., Ye, J., Lu, J., et al. (2018) · Molecules · doi:10.3390/molecules23092346 · Cited by 333
Han, K., Nam, J., Xu, J., Sun, X., Huang, X., Animasahun, O., Achreja, A., Jeon, J. H., Pursley, B., Kamada, N., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00749-2 · Cited by 287
Metadata
- Authors
- Wang, J., Man, G. C. W., Chan, T. H., Kwong, J., & Wang, C. C.
- Affiliations
- Chinese University of Hong Kong (HK)
- Hong Kong Polytechnic University (HK)
- Corresponding author
- Wang, Chi Chiu
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 412
- Pages
- 10-20
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2761665465
- Cited by
- 127
- References
- 44
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 16 · 2023: 11 · 2022: 12 · 2021: 18 · 2020: 29 · 2019: 13 · 2018: 11
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Letters (publishedVersion)
- PubMed (publishedVersion)
- PolyU Institutional Research Archive (Hong Kong Polytechnic University) (submittedVersion)
- Funders
- University of Hong Kong
- Chinese University of Hong Kong
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Agricultural and Biological Sciences › Food Science › Tea Polyphenols and Effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- epigallocatechin gallate, green tea polyphenols, prodrugs, endometrial cancer, tumor angiogenesis, anti-angiogenic therapy, VEGF-A, HIF-1α, PI3K/AKT/mTOR pathway, CXCL12, tumor-associated macrophages, macrophage infiltration, tumor stroma, xenograft models
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Catechin, Cell Movement, Female, Humans, Macrophages, Prodrugs, Tea, Endometrial Neoplasms, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Mice, Chemokine CXCL12
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
